Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug ...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually ...
Gainers: Reliance Global Group (NASDAQ:RELI) +82%. Biofrontera (NASDAQ:BFRI) +49%. Jaguar Health (NASDAQ:JAGX) +43%. IsoPlexis (NASDAQ:ISO) +31%. Aridis Pharmaceuticals (NASDAQ:ARDS) +28%. Petros Pharmaceuticals (NASDAQ:PTPI) +30%. Eqonex (NASDAQ:EQOS) +26%. Quantum-Si incorporated (NASDAQ:QS...
Shares of CytomX Therapeutics (NASDAQ: CTMX) were crashing 40.1% lower as of 11:44 a.m. ET on Tuesday. The steep decline came after the company announced disappointing preliminary results from a phase 2 study evaluating CX-2029 in treating patients with either advanced squamous non-...
Shares of CytomX Therapeutics (NASDAQ:CTMX) are down 28% in post-market trading following the release of interim phase 2 data on CX-2029 in advanced squamous non-small cell lung cancer and head and neck squamous cell carcinoma. Results showed an objective response rate of 18.8% and a disease ...
-Objective response rate of 18.8 percent and disease control rate of 87.5 percent in unselected advanced squamous non-small cell lung cancer. Enrollment continues- -Enrollment completed in advanced head and neck squamous cell carcinoma with objective response rate of 4.0 percent...
CTMX went up 50% since my September coverage but is down to 25% now. They had exciting news about a patent dispute and will present two key misstated datasets in the next 2-3 months. Any pullback here is an opportunity. For further details see: CytomX: Pullbacks Are Oppo...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in vir...
CytomX Therapeutics, Inc. (CTMX) Q3 2021 Earnings Conference Call November 04, 2021 05:00 PM ET Company Participants Chau Cheng - Vice President Investor Relations & Corporate Communications Sean McCarthy - President, Chief Executive Officer & Chairman Carlos Campoy - Chief Financial ...
The following slide deck was published by CytomX Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: CytomX Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...